title: Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma.
authors.forename: G G
authors.initials: GG
authors.lastname: Wulf
authors.forename: J
authors.initials: J
authors.lastname: Hasenkamp
authors.forename: W
authors.initials: W
authors.lastname: Jung
authors.forename: B
authors.initials: B
authors.lastname: Chapuy
authors.forename: L
authors.initials: L
authors.lastname: Truemper
authors.forename: B
authors.initials: B
authors.lastname: Glass
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000074301:CD52 Antigen; D018450:Disease Progression; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000628:therapy*; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy; D033581:Stem Cell Transplantation; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab